Arpida to Restructure and Focus on Key Projects
REINACH, Switzerland, November 27, 2008 /PRNewswire-FirstCall/ -- Arpida announced today that it is refocusing all projects and priorities around the key strategic asset Iclaprim. The company says this is to be seen as a consequence of the negative recommendation of the U.S. Food and Drug Administration (FDA) advisory board on 20 November 2008 regarding the approval of Iclaprim in the U.S.
In the context of the FDA advisory board's recommendation the Arpida board intends to put the company back on a firm footing through cutting costs considerably. To achieve this, the company views the reduction of the workforce by up to 60 employees as inevitable. A consultation process with all employees has been initiated and will lead to decisions by the Board of Directors which will be communicated on 16 December 2008. Board and Management sincerely regret this measure and would like to point out that the company will endeavour to fully assume its social responsibilities. Contact with public authorities on this issue has been established and a social plan will be presented in time.
Arpida will now thoroughly analyse the situation with external experts to determine the future development of Iclaprim. Basis for this analysis will be the full FDA response to the Iclaprim dossier and the publication of the phase II oral step down therapy trial.
"We were very surprised by this very clear negative ruling by the FDA advisory board", CEO Jurgen Raths said. "In particular we are very upset by the steps we are forced to take in regards to our staff. The advisory board's recommendation has come totally unexpected, because we are still convinced that Iclaprim offers a valuable therapeutic asset for the treatment of complicated skin and skin structure infections (cSSSI), especially where MRSA (resistant bacteria called methicillin-resistant staphylococcus aureus) are involved. We will use the FDA's feedback as well as further clinical advice and expertise in our development decisions. We will also continue to cooperate closely with the regulatory agencies in the U.S., Canada and Europe to obtain market authorization for what we think is a valuable asset in the fight against potentially life threatening infections."
About Arpida Ltd.
Arpida is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Contact: Jurgen Raths, President & CEO Phone: +41-61-417-96-66 Harry Welten, CFO Phone: +41-61-417-96-65
CONTACT: Contact: Jurgen Raths, President & CEO, Phone: +41-61-417-96-66;Harry Welten, CFO, Phone: +41-61-417-96-65
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: December 2008
Recommended for you